113 related articles for article (PubMed ID: 9628224)
1. A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.
Ast O; Jentsch KD; Schramm HJ; Hunsmann G; Lüke W; Petry H
J Virol Methods; 1998 Mar; 71(1):77-85. PubMed ID: 9628224
[TBL] [Abstract][Full Text] [Related]
2. A rapid and simple screening method for HIV-1 protease inhibitors using recombinant Escherichia coli.
Kaneto R; Kojima I; Shibamoto N; Nishida H; Okamoto R; Akagawa H; Mizuno S
J Antibiot (Tokyo); 1994 Apr; 47(4):492-5. PubMed ID: 8195050
[No Abstract] [Full Text] [Related]
3. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
Quéré L; Wenger T; Schramm HJ
Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
[TBL] [Abstract][Full Text] [Related]
4. Screening for HIV protease inhibitors by protection against activity-mediated cytotoxicity in Escherichia coli.
Cheng YS; Lo KH; Hsu HH; Shao YM; Yang WB; Lin CH; Wong CH
J Virol Methods; 2006 Oct; 137(1):82-7. PubMed ID: 16849028
[TBL] [Abstract][Full Text] [Related]
5. An E. coli expression system which detoxifies the HIV protease.
Korant BD; Rizzo CJ
Biomed Biochim Acta; 1991; 50(4-6):643-6. PubMed ID: 1801736
[TBL] [Abstract][Full Text] [Related]
6. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
7. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
Maschera B; Furfine E; Blair ED
J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
[TBL] [Abstract][Full Text] [Related]
8. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.
Louis JM; McDonald RA; Nashed NT; Wondrak EM; Jerina DM; Oroszlan S; Mora PT
Eur J Biochem; 1991 Jul; 199(2):361-9. PubMed ID: 2070793
[TBL] [Abstract][Full Text] [Related]
9. A folding inhibitor of the HIV-1 protease.
Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G
Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of human immunodeficiency virus proteases by 'interface peptides'.
Schramm HJ; Boetzel J; Büttner J; Fritsche E; Göhring W; Jaeger E; König S; Thumfart O; Wenger T; Nagel NE; Schramm W
Antiviral Res; 1996 May; 30(2-3):155-70. PubMed ID: 8783807
[TBL] [Abstract][Full Text] [Related]
11. Autoprocessing: an essential step for the activation of HIV-1 protease.
Wan M; Takagi M; Loh BN; Xu XZ; Imanaka T
Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):569-73. PubMed ID: 8687402
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 protease by short peptides derived from the terminal segments of the protease.
Schramm HJ; Breipohl G; Hansen J; Henke S; Jaeger E; Meichsner C; Riess G; Ruppert D; Rücknagel KP; Schäfer W
Biochem Biophys Res Commun; 1992 Apr; 184(2):980-5. PubMed ID: 1575762
[TBL] [Abstract][Full Text] [Related]
13. Interactions of substrates and inhibitors with a family of tethered HIV-1 and HIV-2 homo- and heterodimeric proteinases.
Griffiths JT; Tomchak LA; Mills JS; Graves MC; Cook ND; Dunn BM; Kay J
J Biol Chem; 1994 Feb; 269(7):4787-93. PubMed ID: 8106448
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of HIV-1 protease by interface peptides.
Schramm HJ; Billich A; Jaeger E; Rücknagel KP; Arnold G; Schramm W
Biochem Biophys Res Commun; 1993 Jul; 194(2):595-600. PubMed ID: 8343146
[TBL] [Abstract][Full Text] [Related]
15. A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli.
Stebbins J; Deckman IC; Richardson SB; Debouck C
Anal Biochem; 1996 Nov; 242(1):90-4. PubMed ID: 8923970
[TBL] [Abstract][Full Text] [Related]
16. Screening of inhibitors of HIV-1 protease using an Escherichia coli cell assay.
Büttner J; Dornmair K; Schramm HJ
Biochem Biophys Res Commun; 1997 Apr; 233(1):36-8. PubMed ID: 9144391
[TBL] [Abstract][Full Text] [Related]
17. Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli.
Cheng TJ; Brik A; Wong CH; Kan CC
Antimicrob Agents Chemother; 2004 Jul; 48(7):2437-47. PubMed ID: 15215092
[TBL] [Abstract][Full Text] [Related]
18. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
19. Lipopeptides as dimerization inhibitors of HIV-1 protease.
Schramm HJ; de Rosny E; Reboud-Ravaux M; Büttner J; Dick A; Schramm W
Biol Chem; 1999 May; 380(5):593-6. PubMed ID: 10384967
[TBL] [Abstract][Full Text] [Related]
20. Crystallizable HIV-1 protease derived from expression of the viral pol gene in Escherichia coli.
Danley DE; Geoghegan KF; Scheld KG; Lee SE; Merson JR; Hawrylik SJ; Rickett GA; Ammirati MJ; Hobart PM
Biochem Biophys Res Commun; 1989 Dec; 165(3):1043-50. PubMed ID: 2692557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
